A Study of VCT220 Tablets in Adults With Type 2 Diabetes and Inadequate Blood Glucose Control

A phase 2 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 120 participants.

Also called NCT07872436

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 120 participants (planned count) (from the registry)
Sponsor
Vincentage Pharma Co., Ltd (from the registry)
Registry
  • NCT NCT07872436
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT07872436. Randomized; triple masking; primary purpose treatment. Start 2026-11-01 (anticipated); primary completion 2027-07-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study of VCT220 Tablets in Adults With Type 2 Diabetes and Inadequate Blood Glucose Control
Acronym
VICTOR-DM
Condition
Type 2 Diabetes Mellitus (DM)
Intervention (Drug)
VCT220 tablets
Intervention (Drug)
Placebo
Lead sponsor
Vincentage Pharma Co., Ltd (class: industry)

Record details

Record id
cardio:ct-nct07872436
Content hash
d8ea4da2d81d0409cc1feb545557b47a18c1cd0d7a993ba3ade5c89f8b81a5a1